<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC12098635</article-id><article-id pub-id-type="doi">10.3389/fimmu.2025.1608934</article-id><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Mini Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Mechanisms of autoimmune-mediated paraneoplastic syndromes: immune tolerance and disease pathogenesis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>P&#x000e9;rez-Bucio</surname><given-names>C&#x000e9;sar</given-names></name><uri xlink:href="https://loop.frontiersin.org/people/2946998/overview"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/></contrib><contrib contrib-type="author"><name><surname>Behere</surname><given-names>Anish</given-names></name><uri xlink:href="https://loop.frontiersin.org/people/2851904/overview"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Landegren</surname><given-names>Nils</given-names></name><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/1634957/overview"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib></contrib-group><aff id="aff1">
<institution>Science for Life Laboratory, Department of Medical Biochemistry and Microbiology, Uppsala University</institution>, <addr-line>Uppsala</addr-line>, <country>Sweden</country>
</aff><author-notes><fn fn-type="edited-by"><p>Edited and Reviewed by: Cuiling Zheng, Chinese Academy of Medical Sciences and Peking Union Medical College, China</p></fn><corresp id="fn001">*Correspondence: Nils Landegren, <email xlink:href="mailto:nils.landegren@imbim.uu.se">nils.landegren@imbim.uu.se</email>
</corresp></author-notes><pub-date pub-type="epub"><day>09</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>16</volume><elocation-id>1608934</elocation-id><history><date date-type="received"><day>09</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>21</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025 P&#x000e9;rez-Bucio, Behere and Landegren</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>P&#x000e9;rez-Bucio, Behere and Landegren</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>Paraneoplastic syndromes represent a clinically heterogeneous group of disorders that arise in cancer patients. Although their underlying mechanisms are only partly understood, immune or endocrine mechanisms are believed to play key roles. Autoimmune-mediated paraneoplastic syndromes (AMPS) are typically characterized by the presence of autoantibodies, making their identification important for both AMPS diagnosis and early cancer detection. This review synthesizes emerging insights into the pathogenesis of AMPS, with a particular focus on how genomic instability in cancer cells promotes immune recognition of altered self-proteins. Mechanisms such as ectopic expression, protein modifications (such as isoaspartylation), and gene amplifications can disrupt immune tolerance, leading to autoimmunity. Additionally, chronic inflammation and the formation of tertiary lymphoid structures within the tumor microenvironment contribute to both antitumor immunity and autoimmunity. Immune checkpoint inhibitors (ICIs), have revolutionized cancer treatment by enhancing antitumor immunity, but they can also induce immune-related adverse events (irAEs), some of which mimic AMPS. These irAEs highlight the critical roles of both humoral and cellular immunity in AMPS development. By exploring the relationships between ICI treatment, immune tolerance, and tumor-specific antigens, this review aims to clarify the mechanisms driving AMPS and their dual role in cancer control and immune-mediated disease. Bridging these knowledge gaps may inform the development of novel therapeutic strategies for managing AMPS and in optimizing the use of ICIs in cancer care.</p></abstract><kwd-group><kwd>autoimmune-mediated paraneoplastic syndromes</kwd><kwd>autoantibodies</kwd><kwd>self-tolerance</kwd><kwd>tumor microenvironment</kwd><kwd>immune related adverse events (irAEs)</kwd></kwd-group><funding-group><award-group><funding-source id="cn001"><institution-wrap><institution>Vetenskapsr&#x000e5;det
</institution><institution-id institution-id-type="doi">10.13039/501100004359</institution-id></institution-wrap></funding-source><award-id award-type="contract" rid="cn001">2021-03118</award-id></award-group><award-group><funding-source id="cn002"><institution-wrap><institution>Cancerfonden
</institution><institution-id institution-id-type="doi">10.13039/501100002794</institution-id></institution-wrap></funding-source><award-id award-type="contract" rid="cn002">21 1513 Pj 01 H</award-id></award-group><award-group><funding-source id="cn003"><institution-wrap><institution>G&#x000f6;ran Gustafssons Stiftelser
</institution><institution-id institution-id-type="doi">10.13039/100016408</institution-id></institution-wrap></funding-source><award-id award-type="contract" rid="cn003">2141, 2227</award-id></award-group></funding-group><funding-group><funding-statement>The author(s) declare that financial support was received for the research and/or publication of this article. This work was supported by the Swedish Cancer Society.</funding-statement></funding-group><counts><fig-count count="1"/><table-count count="1"/><equation-count count="0"/><ref-count count="101"/><page-count count="9"/><word-count count="3558"/></counts><custom-meta-group><custom-meta><meta-name>section-in-acceptance</meta-name><meta-value>Cancer Immunity and Immunotherapy</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><label>1</label><title>Introduction</title><p>Paraneoplastic syndromes (PS) comprise a diverse group of disorders that affect different organ systems in cancer patients, arising independently of the primary tumor or its metastases. Their clinical manifestations are often distant from the tumor site and are thought to result from humeral factors produced by cancer cells or by immune system reactions. Due to their rarity and clinical heterogeneity, the reported incidence of PS varies widely, ranging from 7% to 33% of cancer patients (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>). These syndromes typically manifest within &#x000b1;3 years of cancer diagnosis and are more frequently identified after cancer is detected (<xref rid="B3" ref-type="bibr">3</xref>).</p><p>The mechanisms underlying PS are incompletely understood and diverse. Non-autoimmune-mediated PS are often driven by endocrine imbalances (<xref rid="B4" ref-type="bibr">4</xref>), such as hyponatremia, hypercalcemia, or Cushing&#x02019;s syndrome, as well as cytokine dysregulation (<xref rid="B5" ref-type="bibr">5</xref>), including neutrophilia, Trousseau&#x02019;s syndrome, and thrombocytosis. These cases are associated with poor patient outcomes (<xref rid="B5" ref-type="bibr">5</xref>). In contrast, autoimmune-mediated paraneoplastic syndromes are linked to better cancer prognoses, suggesting that autoimmune flares are a sign of enhanced antitumor responses.</p><p>Autoimmune-mediated paraneoplastic syndromes (AMPS) most commonly affect the central nervous system (CNS) but can also manifest in the peripheral nervous system (PNS), skin, or blood (<xref rid="B6" ref-type="bibr">6</xref>). A hallmark of AMPS is the presence of autoantibodies, which have gained attention for their role as disease biomarkers (<xref rid="B7" ref-type="bibr">7</xref>). These autoantibodies are important in the diagnosis of paraneoplastic syndromes and may support early cancer detection in this group of patients. For instance, individual autoantibodies, such as p53 (<xref rid="B8" ref-type="bibr">8</xref>), HER2 (<xref rid="B9" ref-type="bibr">9</xref>), and NY-ESO-1 (<xref rid="B10" ref-type="bibr">10</xref>), as well as autoantibody panels, have shown predictive potential for cancer diagnosis (<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B12" ref-type="bibr">12</xref>). However, these biomarkers still fail to meet clinical standards (<xref rid="B13" ref-type="bibr">13</xref>). Important observations have been made linking cancer alterations with commonly associated autoantibodies and the development of AMPS (<xref rid="T1" ref-type="table">
<bold>Table&#x000a0;1</bold>
</xref>).</p><table-wrap position="float" id="T1"><label>Table&#x000a0;1</label><caption><p>Summary of autoimmune-mediated paraneoplastic syndromes (AMPS).</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Manifestations</th><th valign="top" align="left" rowspan="1" colspan="1">Syndrome</th><th valign="top" align="left" rowspan="1" colspan="1">Underlying Cancers</th><th valign="top" align="left" rowspan="1" colspan="1">Associated Autoantibody</th></tr></thead><tbody><tr><td valign="top" rowspan="9" align="left" colspan="1">Neurological</td><td valign="top" align="left" rowspan="1" colspan="1">Lambert&#x02013;Eaton myasthenic syndrome (<xref rid="B14" ref-type="bibr">14</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">SCLC</td><td valign="top" align="left" rowspan="1" colspan="1">Anti-VGCC (P/Q-type voltage-gated calcium channel)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Paraneoplastic cerebellar degeneration (<xref rid="B15" ref-type="bibr">15</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Lung cancer, ovarian cancer, breast carcinoma, Hodgkin&#x02019;s lymphoma</td><td valign="top" align="left" rowspan="1" colspan="1">Anti-Yo, Anti-Hu, Anti-Tr, Anti-Ri</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Sensory Neuronopathies (<xref rid="B16" ref-type="bibr">16</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Various</td><td valign="top" align="left" rowspan="1" colspan="1">Anti-Hu, Anti-CRPM5, Anti-CV2, Anti-AGO</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Encephalomyelitis (<xref rid="B17" ref-type="bibr">17</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Various</td><td valign="top" align="left" rowspan="1" colspan="1">Anti-Hu</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Limbic encephalitis (<xref rid="B18" ref-type="bibr">18</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">SCLC</td><td valign="top" align="left" rowspan="1" colspan="1">Anti-Hu, Anti-Ma2</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Brainstem encephalitis (<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B19" ref-type="bibr">19</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Lung cancer, testicular cancer</td><td valign="top" align="left" rowspan="1" colspan="1">Anti-Hu, Anti-Ri, Anti-Ma2, Anti-KLHL11</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Opsoclonus myoclonus ataxia syndrome (<xref rid="B20" ref-type="bibr">20</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Breast carcinoma, ovarian carcinoma, SCLC, neuroblastoma (in children)</td><td valign="top" align="left" rowspan="1" colspan="1">Anti-Ri</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Myasthenia Gravis (<xref rid="B21" ref-type="bibr">21</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Thymoma</td><td valign="top" align="left" rowspan="1" colspan="1">Anti-AChR</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Anti-NMDA receptor encephalitis (<xref rid="B22" ref-type="bibr">22</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Teratoma</td><td valign="top" align="left" rowspan="1" colspan="1">Anti-NMDA receptor</td></tr><tr><td valign="top" rowspan="8" align="left" colspan="1">Mucocutaneous</td><td valign="top" align="left" rowspan="1" colspan="1">Polymyositis (<xref rid="B23" ref-type="bibr">23</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Non-Hodgkin lymphoma, lung cancer, bladder cancer</td><td valign="top" align="left" rowspan="1" colspan="1">Anti-Jo-1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Acanthosis nigricans (<xref rid="B24" ref-type="bibr">24</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Gastric carcinoma, lung carcinoma, uterine carcinoma</td><td valign="top" align="left" rowspan="1" colspan="1">N.A.</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Dermatomyositis (<xref rid="B23" ref-type="bibr">23</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Bronchogenic carcinoma, breast carcinoma, ovarian cancer, pancreatic cancer, stomach cancer, colorectal cancer, non-Hodgkin lymphoma</td><td valign="top" align="left" rowspan="1" colspan="1">Anti-Mi-2, Anti-NXP2, Anti-TIF1&#x003b3;</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Leser-Tr&#x000e9;lat sign (<xref rid="B25" ref-type="bibr">25</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Various</td><td valign="top" align="left" rowspan="1" colspan="1">N.A.</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Necrolytic migratory erythema (<xref rid="B26" ref-type="bibr">26</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Glucagonoma</td><td valign="top" align="left" rowspan="1" colspan="1">N.A.</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Sweet&#x02019;s syndrome (<xref rid="B27" ref-type="bibr">27</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Hematologic malignancies</td><td valign="top" align="left" rowspan="1" colspan="1">N.A.</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Leukocytoclastic vasculitis (<xref rid="B28" ref-type="bibr">28</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Leukemia/lymphoma, myelodysplastic syndromes, colon, lung, urologie, multiple myeloma, rhabdomyosarcoma</td><td valign="top" align="left" rowspan="1" colspan="1">N.A.</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Paraneoplastic pemphigus (<xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B30" ref-type="bibr">30</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Non-Hodgkin lymphoma, chronic lymphocytic leukemia, thymoma, Castleman disease, follicular dendritic cell sarcoma</td><td valign="top" align="left" rowspan="1" colspan="1">Anti-Plakin, Anti-Desmoglein</td></tr><tr><td valign="top" rowspan="5" align="left" colspan="1">Rheumatic</td><td valign="top" align="left" rowspan="1" colspan="1">Palmar fasciitis and polyarthritis (<xref rid="B31" ref-type="bibr">31</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Ovarian cancer</td><td valign="top" align="left" rowspan="1" colspan="1">N.A.</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Sj&#x000f6;gren-like syndrome (<xref rid="B32" ref-type="bibr">32</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Non-Hodgkin lymphoma, lung cancer</td><td valign="top" align="left" rowspan="1" colspan="1">Anti-Ro/SSA, Anti-La/SSB</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Polymyalgia rheumatica (<xref rid="B33" ref-type="bibr">33</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Leukemia/lymphoma, myelodysplastic syndromes, colon, lung, renal, prostate, breast cancer</td><td valign="top" align="left" rowspan="1" colspan="1">N.A.</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Systemic Sclerosis (SSc) (<xref rid="B34" ref-type="bibr">34</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Breast, lung, prostate cancer, melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">Anti-RPC-1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Hypertrophic osteoarthropathy (<xref rid="B35" ref-type="bibr">35</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Lung cancer (adenocarcinoma), mesothelioma</td><td valign="top" align="left" rowspan="1" colspan="1">N.A.</td></tr><tr><td valign="top" rowspan="4" align="left" colspan="1">Others</td><td valign="top" align="left" rowspan="1" colspan="1">Membranous glomerulonephritis (<xref rid="B36" ref-type="bibr">36</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Various</td><td valign="top" align="left" rowspan="1" colspan="1">Anti-PLA2R</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Tumor-induced osteomalacia (<xref rid="B37" ref-type="bibr">37</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Hemangiopericytoma, phosphaturic mesenchymal tumor</td><td valign="top" align="left" rowspan="1" colspan="1">N.A.</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Stauffer syndrome (<xref rid="B38" ref-type="bibr">38</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Renal cell carcinoma</td><td valign="top" align="left" rowspan="1" colspan="1">N.A.</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Cancer-Associated Retinopathy (CAR) (<xref rid="B39" ref-type="bibr">39</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Melanoma, SCLC</td><td valign="top" align="left" rowspan="1" colspan="1">Anti-recoverin, Anti-transducin</td></tr></tbody></table></table-wrap><p>Despite advances in autoantibody research, the cellular and molecular mechanisms underlying AMPS pathogenesis remain poorly understood. This review aims to summarize the current state of research on AMPS exploring the mechanisms driving autoimmune disorders in cancer. Specifically, it will address how ectopic expression, protein structural alterations, and overexpression of self-proteins may trigger autoimmune responses. Overlapping clinical presentations between AMPS and immune-related adverse events (irAEs) of immune checkpoint inhibitor (ICI) treatment will be discussed, highlighting the need to understand autoimmunity in cancer. Further, the roles of chronic inflammation within the tumor microenvironment (TME) and localized immune tolerance in sustaining these responses will be examined. With this discussion, we aim to bridge existing knowledge gaps and provide a framework to better understand AMPS pathogenesis.</p></sec><sec id="s2"><label>2</label><title>Protein overexpression, ectopic expression and structure changes drive autoimmunity in cancer</title><p>Ectopic expression refers to the production of a self-protein in atypical tissues. Malignant cells frequently exhibit ectopic expression of otherwise tissue-restricted proteins as a consequence of genomic instability. Genomic instability may also trigger missense mutations that may lead to changes in protein structure. Similarly, an antigen may be overexpressed due to chromosome amplifications. In cancer, any of these alterations can induce immune recognition and targeting of malignant cells. In the following AMPS cases, evidence has been provided of how genetic or proteomic alterations can lead to immune recognition and the development of autoimmunity.</p><sec id="s2_1"><label>2.1</label><title>Anti-Hu: encephalomyelitis</title><p>The Hu protein family comprises RNA-binding proteins primarily expressed in neuronal cells, where they play a role in mRNA stabilization and translation (<xref rid="B40" ref-type="bibr">40</xref>). HuD, a member of this family, is known to be expressed in several cancer types (<xref rid="B41" ref-type="bibr">41</xref>). Small cell lung cancer (SCLC) patients with paraneoplastic sensory neuropathy or encephalomyelitis present high anti-Hu antibody titers (<xref rid="B42" ref-type="bibr">42</xref>). These antibodies target tumor-expressed Hu proteins, which would otherwise be restricted to neuronal cells. Interestingly, while all SCLC patients with neurological AMPS are anti-Hu positive, 17% of all SCLC patients, irrespective of paraneoplastic presentation, harbor detectable anti-Hu titers (<xref rid="B43" ref-type="bibr">43</xref>).</p><p>Changes in protein structure can occur after protein folding, contributing to the development of autoimmunity. HuD (also known as ELAVL4) commonly undergoes isoaspartylation, a modification that can impair its physiological activity. In the healthy CNS, PIMT (peptidyl-isomerase methyltransferase) repairs this damage, restoring HuD to its native, functional form (<xref rid="B44" ref-type="bibr">44</xref>). However, because PIMT expression is restricted to certain tissues (<xref rid="B45" ref-type="bibr">45</xref>), HuD-expressing tumors accumulate isoaspartylated HuD. This ectopically expressed protein variant can be recognized as a non-self-antigen, triggering an immune response in patients with HuD-expressing cancers. In rare cases, the development of anti-HuD autoantibodies may lead to cross-reactivity and recognition of the wild-type HuD protein in the CNS (<xref rid="B46" ref-type="bibr">46</xref>).</p><p>Pulido M. and colleagues tested serum from seven anti-HuD positive SCLC patients, four of whom had paraneoplastic syndromes against both native and isoaspartylated HuD. All seven samples reacted with both protein isoforms, suggesting not only immune stimulation of isoaspartylated HuD but also cross-reactivity toward native HuD (<xref rid="B46" ref-type="bibr">46</xref>). This cross-reactivity explains the paraneoplastic presentation in some of these patients. Isoaspartyl post-translational modifications has been shown to cause immunogenicity and break self-tolerance before (<xref rid="B47" ref-type="bibr">47</xref>).</p></sec><sec id="s2_2"><label>2.2</label><title>Anti-recoverin: cancer-associated retinopathy</title><p>Cancer-associated retinopathy (CAR) has been observed across various cancer types, predominantly in SCLC and breast cancer. CAR is characterized by progressive sight loss due to autoimmune targeting of retinal proteins. The rarity of this syndrome has made it difficult to reliably identify the underlying autoantibody, although markers against specific retinal proteins like transducin and recoverin have been reported (<xref rid="B48" ref-type="bibr">48</xref>, <xref rid="B49" ref-type="bibr">49</xref>).</p><p>Sera from 143 cancer patients (99 SCLC and 44 non-small cell lung cancer [NSCLC]) was tested for anti-recoverin antibodies by immunoblotting. Anti-recoverin positivity was observed in 15% and 20% of SCLC and NSCLC cases, respectively. No healthy controls showed anti-recoverin positivity (<xref rid="B50" ref-type="bibr">50</xref>). Tumor samples were available from 44 SCLC and 40 NSCLC patients. Recoverin expression was detected by immunohistochemistry in 68% of SCLC and 85% of NSCLC patients (<xref rid="B50" ref-type="bibr">50</xref>). All symptomatic CAR-SCLC patients test positive for anti-recoverin autoantibodies, likely due to ectopic expression of retinal proteins (<xref rid="B51" ref-type="bibr">51</xref>). A clinical report of a uterine carcinosarcoma patient also revealed serum positivity for anti-recoverin antibodies. Postmortem immunofluorescence analysis detected recoverin expression in the tumor cells (<xref rid="B52" ref-type="bibr">52</xref>).</p></sec><sec id="s2_3"><label>2.3</label><title>Anti-VGCC: paraneoplastic LEMS</title><p>SCLC cells can aberrantly express voltage-gated calcium channels (VGCCs), typically found in presynaptic nerve terminals of the CNS and at neuromuscular junctions (<xref rid="B53" ref-type="bibr">53</xref>). The autoimmune disorder Lambert&#x02013;Eaton myasthenic syndrome (LEMS) arises from the production of anti-P/Q-type VGCC autoantibodies, leading to muscle weakness, dry mouth, and neurodegenerative features (<xref rid="B54" ref-type="bibr">54</xref>). LEMS is a paraneoplastic syndrome in approximately 62% of cases (<xref rid="B55" ref-type="bibr">55</xref>), with all SCLC-LEMS patients exhibiting anti-P/Q-type VGCC autoantibodies (<xref rid="B56" ref-type="bibr">56</xref>), and 25% of them presenting neurological symptoms in addition to the predominant muscle weakness (<xref rid="B57" ref-type="bibr">57</xref>).</p><p>Not all anti-VGCC positive patients develop LEMS. One study reported that half of the patients (5 out of 10) with anti-VGCC autoantibodies did not exhibit any symptoms of LEMS or neurological damage (<xref rid="B58" ref-type="bibr">58</xref>).</p></sec><sec id="s2_4"><label>2.4</label><title>Anti-NMDAR: encephalitis</title><p>Another autoimmune disorder with neurological symptoms is anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis, which involves the disruption of a key receptor for excitatory neurotransmission specific to the CNS (<xref rid="B59" ref-type="bibr">59</xref>). NMDAR is often expressed in ovarian teratomas (OT), and approximately 37% of anti-NMDAR encephalitis cases are associated with ovarian teratomas, where the encephalitis resolves after tumor resection (<xref rid="B60" ref-type="bibr">60</xref>). Further, reports have shown that in these cases, the antibodies targeting NMDAR are generated within the tumor tissue (<xref rid="B61" ref-type="bibr">61</xref>). Moreover, patients with ovarian teratomas but without neurological symptoms do not exhibit anti-NMDAR antibodies, supporting their association with neurological complications (<xref rid="B62" ref-type="bibr">62</xref>&#x02013;<xref rid="B64" ref-type="bibr">64</xref>).</p></sec><sec id="s2_5"><label>2.5</label><title>Anti-RPC1: systemic sclerosis</title><p>Anti-RNA polymerase III subunit C (RPC1) autoantibodies are commonly found in patients with systemic sclerosis (SSc) (<xref rid="B65" ref-type="bibr">65</xref>). A study of eight RPC+ paraneoplastic SSc patients with different forms of cancer revealed that the tumors in five of these patients exhibited genetic alterations in the <italic>POLR3A</italic> locus. Three of them had a missense mutation, and all five presented with loss of heterozygosity. Every patient harbored at least one genetic alteration, strongly suggesting that these genetic changes triggered an immune response against both the cancer-expressed and the wild-type RNA polymerase protein (<xref rid="B66" ref-type="bibr">66</xref>).</p></sec><sec id="s2_6"><label>2.6</label><title>Anti-Yo: cerebellar degeneration</title><p>Cerebellar degeneration-related protein 2 (CDR2) and CDR2-like (CDR2L), are neuronal cell proteins typically expressed in Purkinje cells (referred to as Yo antigens) (<xref rid="B67" ref-type="bibr">67</xref>) and have been implicated in paraneoplastic cerebellar degeneration. Anti-Yo autoantibody titers were found in a cohort of patients with paraneoplastic cerebellar damage due to ovarian carcinoma. In this group, 17 of 17 tumor samples tested had at least one genetic alteration. Specifically, 59% of cases exhibited a chromosome 17q gain, where CDR2L and CDR2 are located, and 65% of cases had mutations in either or both <italic>CDR2L</italic>/<italic>CDR2</italic> genes (<xref rid="B68" ref-type="bibr">68</xref>).</p><p>Similarly, a study of 29 anti-Yo positive breast carcinoma patients revealed that all had at least one genetic alteration such as mutations (62.5%), amplifications (61.5%), or 17q gains (38.4%) in the <italic>CDR2L</italic>/<italic>CDR2</italic> genes, which also contributed to paraneoplastic cerebellar degeneration (<xref rid="B69" ref-type="bibr">69</xref>). An interesting observation discussed by the authors is that the tumors were highly infiltrated by B and T cells and tended to metastasize early. Not only showing strong anti-tumor responses but also a high tumor invasiveness in this AMPS cohort (<xref rid="B69" ref-type="bibr">69</xref>).</p></sec><sec id="s2_7"><label>2.7</label><title>Anti-AChR: myasthenia gravis</title><p>Myasthenia Gravis (MG) is an autoimmune disorder that is tightly linked to neoplasia, particularly thymoma. It is estimated that 30% to 40% of thymoma patients develop MG (<xref rid="B70" ref-type="bibr">70</xref>, <xref rid="B71" ref-type="bibr">71</xref>). Unlike many cancer-associated autoimmune syndromes, MG is not associated with a favorable prognosis in thymoma patients (<xref rid="B72" ref-type="bibr">72</xref>). MG is characterized by progressive muscle weakness that worsens with physical movement, driven by autoantibody activity against neuromuscular-associated proteins. The most common MG autoantibody is anti-acetylcholine receptor (AChR) (85% of MG cases (<xref rid="B73" ref-type="bibr">73</xref>)), a protein responsible for signal transmission at the neuromuscular junction (<xref rid="B74" ref-type="bibr">74</xref>).</p><p>MG-associated thymoma and non-paraneoplastic thymoma tumors were compared by bulk RNA sequencing on two independent studies (<xref rid="B75" ref-type="bibr">75</xref>, <xref rid="B76" ref-type="bibr">76</xref>). Both results showed AChR overexpression in MG-associated thymoma samples - 3 and 1.07 fold increase respectively - initially suggesting that protein overexpression may drive autoantibody production. Interestingly, the <italic>NEFM</italic> (Neurofilament Medium Chain) gene coding for a neuronal protein NEFM was found to be highly expressed (30-fold (<xref rid="B75" ref-type="bibr">75</xref>) and &#x0003e;100-fold (<xref rid="B76" ref-type="bibr">76</xref>)) in MG-associated thymoma cases. Schultz et&#x000a0;al. (1999) showed that NEFM contains a linear epitope that closely resembles an AChR antigen, and that NEFM-specific antibodies could recognize the AChR -subunit, suggesting that anti-AChR activity is promoted by immunity against NEFM (<xref rid="B77" ref-type="bibr">77</xref>). Similar epitopes in thymoma MG samples that may trigger cross-reacting antibodies against titin and RYR have also been proposed (<xref rid="B75" ref-type="bibr">75</xref>).</p></sec></sec><sec id="s3"><label>3</label><title>Immune checkpoint inhibitors and immune-related adverse events</title><p>In the previous section, we discussed cases of AMPS that arise independently of cancer treatment. Immune-modulating treatments such as ICIs can trigger irAEs, some of which share similarities with AMPS. This has become increasingly relevant given the quick adaptation of ICIs into the clinic, driven by their ability to improve overall survival while causing fewer general adverse effects than traditional therapies (<xref rid="B78" ref-type="bibr">78</xref>&#x02013;<xref rid="B80" ref-type="bibr">80</xref>).</p><p>Immune checkpoints prevent overactivation of cytotoxic T cells, ensuring that self-tolerance is maintained. PD-L1 for instance, dampens T cell cytotoxicity through interaction with PD-1 expressed by T cells. This regulatory function is controlled by immune cells but can also be mediated in immune-privileged tissues such as the lung, liver, and placenta (<xref rid="B81" ref-type="bibr">81</xref>). Cancer cells exploit immune checkpoints by upregulating inhibitory signals such as PD-L1 (interacting with PD-1 (<xref rid="B82" ref-type="bibr">82</xref>) and CD80 (interacting with CTLA-4 (<xref rid="B83" ref-type="bibr">83</xref>)) to evade immune destruction and create an immunosuppressive tumor microenvironment. By inhibiting these pathways, ICIs enhance T cell recognition of cancer cells, but also increase the risk of autoimmunity, particularly in individuals with a history of autoimmune disorders (<xref rid="B84" ref-type="bibr">84</xref>, <xref rid="B85" ref-type="bibr">85</xref>).</p><p>Several irAEs observed in ICI-treated patients overlap with AMPS; disorders like myositis, encephalitis, SSc, and MG are among the most prevalent overlapping conditions. While clinical similarities suggest that ICI treatment could increase the risk of developing AMPS, there are many contrasting features between them. For example, a systematic review by Buckley et&#x000a0;al. (2025) on ICI-related encephalitis, found that only 46.9% of cases were autoantibody-positive (<xref rid="B86" ref-type="bibr">86</xref>), different from AMPS cases, where autoantibodies are significantly more frequent (100% in SCLC paraneoplastic encephalitis (<xref rid="B42" ref-type="bibr">42</xref>), 75% in general paraneoplastic encephalitides (<xref rid="B87" ref-type="bibr">87</xref>)). Similarly, in Hamada et&#x000a0;al. (2021), only 67% of ICI-related MG cases were positive for any MG-related autoantibody (<xref rid="B88" ref-type="bibr">88</xref>) compared to over 95% in thymoma MG (<xref rid="B89" ref-type="bibr">89</xref>). A similar trend of seronegative cases has been noted in ICI-related SSc (<xref rid="B90" ref-type="bibr">90</xref>).</p><p>While seropositive irAEs seem to be a case where ICIs facilitate development of AMPS, a significant proportion of irAE cases are seronegative and appear to have mechanistic differences, where T cell cytotoxicity is the main driver of autoimmunity. Whether these autoreactive T cells are expanded through antitumor immunity, as observed in AMPS, remains to be explored.</p><p>Given the high prevalence of severe irAEs of ICI-treated patients (20% (<xref rid="B91" ref-type="bibr">91</xref>)), predictive screening tools could help physicians tailor treatment strategies to individual patients. Biomarkers such as blood counts, autoantibodies, HLA genotype, and microRNA expression profiles have been identified as prognostic and diagnostic tools in autoimmune diseases (<xref rid="B92" ref-type="bibr">92</xref>). Several studies suggest that pre-existing autoantibodies may indicate an increased risk of developing irAEs following ICI therapy (<xref rid="B93" ref-type="bibr">93</xref>, <xref rid="B94" ref-type="bibr">94</xref>). Screening for autoantibodies before initiating ICI therapy could help classify patients based on their likelihood of developing severe irAEs, enabling safer and personalized treatment approaches.</p></sec><sec id="s4"><label>4</label><title>Chronic inflammation and localized tolerance breaks</title><p>While the presence of autoantibodies is a hallmark of AMPS, not all patients with detectable autoantibodies develop autoimmune symptoms. This discrepancy suggests that additional factors, such as chronic inflammation and localized immune responses within the TME, may determine whether autoimmunity manifests systemically. Understanding these factors is critical for understanding the connection between antitumor immunity and autoimmune pathology.</p><p>The disorders summarized earlier demonstrate that AMPS patients harbor autoantibodies capable of inducing immune responses with both cancer-resolving and autoimmune consequences. However, it remains unclear why some patients with autoantibodies benefit from a stronger antitumor response without developing systemic autoimmunity. This observation points to the importance of additional immune triggers beyond humoral activity in the development of AMPS.</p><p>Strong antitumor responses, a common feature of AMPS patients, are often accompanied by the presence of tertiary lymphoid structures (TLS) within the chronically inflamed TME (<xref rid="B95" ref-type="bibr">95</xref>). TLS are organized immune cell aggregates comprising T cells, B cells, dendritic cells, and macrophages. Functionally resembling secondary lymphoid organs (SLO), TLS promote antigen presentation, B cell priming, and T cell activation (<xref rid="B96" ref-type="bibr">96</xref>). In some AMPS cases, the autoimmune response is mediated entirely within the tumor. For example, Al-Diwani et&#x000a0;al. (2022) observed that ex vivo cultures of B cells dissociated from ovarian teratomas generated anti-NMDAR antibodies, while B cells from cervical lymph nodes did not produce autoantibodies after tumor resection. This finding supports the idea that autoimmunity is initiated within the tumor-associated TLS (<xref rid="B61" ref-type="bibr">61</xref>). Similarly, Mazor et&#x000a0;al. (2022) demonstrated that tumor-specific B cells are primed and clonally expanded within the tumor, often originating from naturally occurring self-reactive B cells (<xref rid="B97" ref-type="bibr">97</xref>). T cells can also expand and generate antitumor responses within the TLS (<xref rid="B98" ref-type="bibr">98</xref>). These findings suggest that TLS facilitate localized antitumor immunity, allowing B and T cells to target self-antigens without eliciting systemic autoimmunity.</p><p>This localized immune activity aligns with the observed improved patient prognosis in the presence of TLS (<xref rid="B99" ref-type="bibr">99</xref>, <xref rid="B100" ref-type="bibr">100</xref>). Many AMPS cases reviewed here, such as anti-NMDAR encephalitis and anti-Yo cerebellar degeneration, involve highly infiltrated tumors (<xref rid="B60" ref-type="bibr">60</xref>, <xref rid="B68" ref-type="bibr">68</xref>, <xref rid="B69" ref-type="bibr">69</xref>). TLS-mediated immunity represents a controlled break in immune tolerance, enabling effective clearance of malignant cells. While circulating autoantibodies are detectable in patient serum, T cells are typically confined to the tumor. A breach in this localization (where T cells migrate from the tumor into circulation) could be the defining trigger for systemic AMPS.</p><p>Activated T cells tend to accumulate in inflamed tissues due to retention signals such as the chemokine CXCL10 (<xref rid="B101" ref-type="bibr">101</xref>). In the absence of systemic inflammation or additional chronic inflammatory events, these T cells are unlikely to enter the bloodstream. However, in cases of invasive cancers with high levels of circulating tumor cells or early metastatic spread, inflammation at the tumor periphery may promote signals that induce T cell migration. This process could extend the anti-self immune response to healthy tissues, contributing to the onset of paraneoplastic syndromes (<xref rid="f1" ref-type="fig">
<bold>Figure&#x000a0;1</bold>
</xref>).</p><fig position="float" id="f1"><label>Figure&#x000a0;1</label><caption><p>Overview of the pathogenesis of autoimmune-mediated paraneoplastic syndromes. 1. Immune recognition of a tumor occurs through <bold>(A)</bold> antigen overexpression, <bold>(B)</bold> altered protein structure, or <bold>(C)</bold> ectopic antigen expression, initiating an immune response and promoting inflammation. 2. Chronic inflammation within the tumor microenvironment supports the formation of tertiary lymphoid structures (TLS). 3. As the TLS matures, it facilitates the activation of autoreactive tumor-targeting T cells and autoantibody-producing plasma cells, leading to a highly infiltrated tumor. 4a. A robust immune response successfully eliminates the tumor without triggering autoimmune symptoms. While autoantibodies remain detectable in circulation, autoreactive B and T cells remain localized within the tumor microenvironment. 4b. In contrast, remote inflammatory events can recruit T cells, promoting the extravasation of autoreactive T cells. Once in circulation, these T cells can recognize and attack healthy tissues, leading to autoimmunity. Created in BioRender. Perez Bucio, <bold>(C)</bold> (2025) <ext-link xlink:href="https://BioRender.com/x3cnql9" ext-link-type="uri">https://BioRender.com/x3cnql9</ext-link>.</p></caption><graphic xlink:href="fimmu-16-1608934-g001" position="float"/></fig><p>Recent studies suggest that a humoral immune response alone is insufficient to trigger autoimmune symptoms but rather serves as a marker of broken self-antigen tolerance. For instance, in paraneoplastic SSc (<xref rid="B66" ref-type="bibr">66</xref>) and anti-Yo-related paraneoplastic cerebellar degeneration (<xref rid="B68" ref-type="bibr">68</xref>, <xref rid="B69" ref-type="bibr">69</xref>), the majority of patients exhibited highly invasive or early metastatic malignancies. This suggests that the expansion of an immune response beyond the tumor, driven by T cell migration, could trigger autoimmune disorders. In contrast, patients with autoantibodies but no paraneoplastic symptoms often have a better prognosis, indicating that localized breaches in self-tolerance, mediated by TLS in the TME, serve as a controlled mechanism for combating malignancy.</p><p>A break in localized self-tolerance may be the defining trigger for paraneoplastic syndromes. This could explain the high specificity but low sensitivity of autoantibody markers; only a subset of autoantibody-positive patients, presumably those with T cell extravasation into the bloodstream due to extended inflammation, develop paraneoplastic features. Tumor-associated TLS are linked with better prognosis and higher immune infiltration, underscoring their role in cancer immunity. Treatment with ICIs can also facilitate the development of autoimmunity through mechanisms that are often independent of autoantibodies.</p></sec><sec sec-type="conclusion" id="s5"><label>5</label><title>Conclusion</title><p>The roles of autoantibodies and T cell autoreactivity in cancer-related autoimmunity remain incompletely understood, as preclinical and clinical data are still limited. A deeper understanding of AMPS could help us clarify the intersection of TLS biology, immune tolerance, and cancer immunity. Resolving how localized immune responses within the tumor microenvironment contribute to either paraneoplastic syndromes or effective tumor resolution may uncover novel therapeutic targets and biomarkers. The similarities between AMPS and ICI-induced irAEs evidence the complex balance between antitumor activity and autoimmunity, highlighting the need for personalized approaches to cancer immunotherapy. Future research focused on unraveling the mechanisms underlying TLS formation, T cell migration, and systemic immune tolerance breaks, will enable a deeper understanding of these processes and will improve both cancer treatment and the management of autoimmune complications.</p></sec></body><back><sec sec-type="author-contributions" id="s6"><title>Author contributions</title><p>CP: Software, Writing &#x02013; original draft, Visualization, Conceptualization. AB: Data curation, Conceptualization, Writing &#x02013; review &#x00026; editing, Validation, Supervision. NL: Funding acquisition, Validation, Conceptualization, Supervision, Project administration, Writing &#x02013; review &#x00026; editing.</p></sec><sec sec-type="COI-statement" id="s8"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="s9"><title>Generative AI statement</title><p>During the preparation of this work the author(s) used ChatGPT-4 by Open AI in order to edit contents of this manuscript and refine the language of this manuscript. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the published article. The author(s) declare that Generative AI was used in the creation of this manuscript.</p></sec><sec sec-type="disclaimer" id="s10"><title>Publisher&#x02019;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zuffa</surname><given-names>M</given-names></name><name><surname>Kubancok</surname><given-names>J</given-names></name><name><surname>Rusn&#x000e1;k</surname><given-names>I</given-names></name><name><surname>Mensatoris</surname><given-names>K</given-names></name><name><surname>Horv&#x000e1;th</surname><given-names>A</given-names></name></person-group>. <article-title>Early paraneoplastic syndrome in medical oncology: clinicopathological analysis of 1694 patients treated over 20 years</article-title>. <source>Neoplasma</source>. (<year>1984</year>) <volume>31</volume>:<page-range>231&#x02013;6</page-range>.</mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Moldovan</surname><given-names>T</given-names></name><name><surname>Boynton</surname><given-names>D</given-names></name><name><surname>Kuperus</surname><given-names>J</given-names></name><name><surname>Parker</surname><given-names>J</given-names></name><name><surname>Noyes</surname><given-names>SL</given-names></name><name><surname>Brede</surname><given-names>CM</given-names></name><etal/></person-group>. <article-title>Incidence and clinical relevance of paraneoplastic syndromes in patients with renal cell carcinoma</article-title>. <source>Urol Oncol Semin Orig Investig</source>. (<year>2023</year>) <volume>41</volume>:<fpage>392</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.urolonc.2023.06.015</pub-id>
</mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pelosof</surname><given-names>LC</given-names></name><name><surname>Gerber</surname><given-names>DE</given-names></name></person-group>. <article-title>Paraneoplastic syndromes: an approach to diagnosis and treatment</article-title>. <source>Mayo Clin Proc</source>. (<year>2010</year>) <volume>85</volume>:<page-range>838&#x02013;54</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.4065/mcp.2010.0099</pub-id>
</mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dimitriadis</surname><given-names>GK</given-names></name><name><surname>Angelousi</surname><given-names>A</given-names></name><name><surname>Weickert</surname><given-names>MO</given-names></name><name><surname>Randeva</surname><given-names>HS</given-names></name><name><surname>Kaltsas</surname><given-names>G</given-names></name><name><surname>Grossman</surname><given-names>A</given-names></name></person-group>. <article-title>Paraneoplastic endocrine syndromes</article-title>. <source>Endocr Relat Cancer</source>. (<year>2017</year>) <volume>24</volume>:<page-range>R173&#x02013;90</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1530/erc-17-0036</pub-id>
</mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kanaji</surname><given-names>N</given-names></name></person-group>. <article-title>Prognosis of patients with paraneoplastic syndromes associated with lung cancer</article-title>. <source>Austin J Pulm Respir Med</source>. (<year>2014</year>) <volume>1</volume>:<fpage>1006</fpage>.</mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Darnell</surname><given-names>RB</given-names></name><name><surname>Posner</surname><given-names>JB</given-names></name></person-group>. <source>Paraneoplastic syndromes</source>. <publisher-name>198 Madison Avenue, New York, New York 10016: Oxford University Press</publisher-name> (<year>2010</year>).</mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chatterjee</surname><given-names>M</given-names></name><name><surname>Hurley</surname><given-names>LC</given-names></name><name><surname>Tainsky</surname><given-names>MA</given-names></name></person-group>. <article-title>Paraneoplastic antigens as biomarkers for early diagnosis of ovarian cancer</article-title>. <source>Gynecol Oncol Rep</source>. (<year>2017</year>) <volume>21</volume>:<fpage>37</fpage>&#x02013;<lpage>44</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.gore.2017.06.006</pub-id>
<pub-id pub-id-type="pmid">28653032</pub-id>
</mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Meng</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>L</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Du</surname><given-names>Z</given-names></name></person-group>. <article-title>Potential diagnostic value of serum p53 antibody for detecting colorectal cancer: a meta-analysis</article-title>. <source>Oncol Lett</source>. (<year>2018</year>) <volume>16</volume>:<page-range>3729&#x02013;36</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3892/ol.2018.8070</pub-id>
</mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tabuchi</surname><given-names>Y</given-names></name><name><surname>Shimoda</surname><given-names>M</given-names></name><name><surname>Kagara</surname><given-names>N</given-names></name><name><surname>Naoi</surname><given-names>Y</given-names></name><name><surname>Tanei</surname><given-names>T</given-names></name><name><surname>Shimomura</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Protective effect of naturally occurring anti-HER2 autoantibodies on breast cancer</article-title>. <source>Breast Cancer Res Treat</source>. (<year>2016</year>) <volume>157</volume>:<fpage>55</fpage>&#x02013;<lpage>63</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s10549-016-3801-4</pub-id>
<pub-id pub-id-type="pmid">27113738</pub-id>
</mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Saito</surname><given-names>T</given-names></name><name><surname>Kurokawa</surname><given-names>Y</given-names></name><name><surname>Fujitani</surname><given-names>K</given-names></name><name><surname>Kawabata</surname><given-names>R</given-names></name><name><surname>Takeno</surname><given-names>A</given-names></name><name><surname>Mikami</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Serum NY-ESO-1 antibody as a predictive biomarker for postoperative recurrence of gastric cancer: a multicenter prospective observational study</article-title>. <source>Br J Cancer</source>. (<year>2024</year>) <volume>130</volume>:<page-range>1157&#x02013;65</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41416-023-02540-3</pub-id>
</mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Patel</surname><given-names>AJ</given-names></name><name><surname>Tan</surname><given-names>T</given-names></name><name><surname>Richter</surname><given-names>AG</given-names></name><name><surname>Naidu</surname><given-names>B</given-names></name><name><surname>Blackburn</surname><given-names>JM</given-names></name><name><surname>Middleton</surname><given-names>GW</given-names></name></person-group>. <article-title>A highly predictive autoantibody-based biomarker panel for prognosis in early-stage NSCLC with potential therapeutic implications</article-title>. <source>Br J Cancer</source>. (<year>2021</year>) <volume>126</volume>:<page-range>238&#x02013;46</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41416-021-01572-x</pub-id>
</mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Ren</surname><given-names>T</given-names></name><name><surname>Yin</surname><given-names>Y</given-names></name></person-group>. <article-title>Autoantibodies as diagnostic biomarkers for lung cancer: a systematic review</article-title>. <source>Cell Death Discov</source>. (<year>2019</year>) <volume>5</volume>:<fpage>126</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41420-019-0207-1</pub-id>
<pub-id pub-id-type="pmid">31396403</pub-id>
</mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zaenker</surname><given-names>P</given-names></name><name><surname>Ziman</surname><given-names>MR</given-names></name></person-group>. <article-title>Serologic autoantibodies as diagnostic cancer biomarkers&#x02014;a review</article-title>. <source>Cancer Epidemiol Biomarkers Prev</source>. (<year>2013</year>) <volume>22</volume>:<page-range>2161&#x02013;81</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1158/1055-9965.epi-13-0621</pub-id>
</mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Titulaer</surname><given-names>MJ</given-names></name><name><surname>Lang</surname><given-names>B</given-names></name><name><surname>Verschuuren</surname><given-names>JJ</given-names></name></person-group>. <article-title>Lambert&#x02013;Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies</article-title>. <source>Lancet Neurol</source>. (<year>2011</year>) <volume>10</volume>:<page-range>1098&#x02013;107</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/s1474-4422(11)70245-9</pub-id>
</mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Graus</surname><given-names>F</given-names></name><name><surname>Saiz</surname><given-names>A</given-names></name><name><surname>Dalmau</surname><given-names>J</given-names></name></person-group>. <article-title>Antibodies and neuronal autoimmune disorders of the CNS</article-title>. <source>J Neurol</source>. (<year>2009</year>) <volume>257</volume>:<page-range>509&#x02013;17</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s00415-009-5431-9</pub-id>
</mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Moritz</surname><given-names>CP</given-names></name><name><surname>Tholance</surname><given-names>Y</given-names></name><name><surname>Boutahar</surname><given-names>N</given-names></name><name><surname>Borowczyk</surname><given-names>C</given-names></name><name><surname>Berger</surname><given-names>AE</given-names></name><name><surname>Paul</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>The antibody repertoire of autoimmune sensory neuronopathies targets pathways of the innate and adaptative immune system. An autoantigenomic approach</article-title>. <source>J Transl Autoimmun</source>. (<year>2025</year>) <volume>8</volume>:<elocation-id>100277</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.jtauto.2025.100277</pub-id>
</mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dalmau</surname><given-names>J</given-names></name><name><surname>Graus</surname><given-names>F</given-names></name><name><surname>Rosenblum</surname><given-names>MK</given-names></name><name><surname>Posner</surname><given-names>JB</given-names></name></person-group>. <article-title>Anti-HU-associated paraneoplastic encephalomyelitis/sensory neuronopathy: a clinical study of 71 patients</article-title>. <source>Medicine</source>. (<year>1992</year>) <volume>71</volume>:<fpage>59</fpage>&#x02013;<lpage>72</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1097/00005792-199203000-00001</pub-id>
<pub-id pub-id-type="pmid">1312211</pub-id>
</mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lancaster</surname><given-names>E</given-names></name><name><surname>Dalmau</surname><given-names>J</given-names></name></person-group>. <article-title>Neuronal autoantigens&#x02014;pathogenesis, associated disorders and antibody testing</article-title>. <source>Nat Rev Neurol</source>. (<year>2012</year>) <volume>8</volume>:<page-range>380&#x02013;90</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/nrneurol.2012.99</pub-id>
</mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mandel-Brehm</surname><given-names>C</given-names></name><name><surname>Dubey</surname><given-names>D</given-names></name><name><surname>Kryzer</surname><given-names>TJ</given-names></name><name><surname>O&#x02019;Donovan</surname><given-names>BD</given-names></name><name><surname>Tran</surname><given-names>B</given-names></name><name><surname>Vazquez</surname><given-names>SE</given-names></name><etal/></person-group>. <article-title>Kelch-like protein 11 antibodies in Seminoma-Associated paraneoplastic encephalitis</article-title>. <source>N Engl J Med</source>. (<year>2019</year>) <volume>381</volume>:<fpage>47</fpage>&#x02013;<lpage>54</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1056/nejmoa1816721</pub-id>
<pub-id pub-id-type="pmid">31269365</pub-id>
</mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pranzatelli</surname><given-names>MR</given-names></name></person-group>. <article-title>The immunopharmacology of the opsoclonus-myoclonus syndrome</article-title>. <source>Clin Neuropharmacol</source>. (<year>1996</year>) <volume>19</volume>:<fpage>1</fpage>&#x02013;<lpage>47</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1097/00002826-199619010-00001</pub-id>
<pub-id pub-id-type="pmid">8867515</pub-id>
</mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Skeie</surname><given-names>GO</given-names></name><name><surname>Romi</surname><given-names>F</given-names></name></person-group>. <article-title>Paraneoplastic myasthenia gravis: immunological and clinical aspects</article-title>. <source>Eur J Neurol</source>. (<year>2008</year>) <volume>15</volume>:<page-range>1029&#x02013;33</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1111/j.1468-1331.2008.02242.x</pub-id>
</mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dalmau</surname><given-names>J</given-names></name><name><surname>Gleichman</surname><given-names>AJ</given-names></name><name><surname>Hughes</surname><given-names>EG</given-names></name><name><surname>Rossi</surname><given-names>JE</given-names></name><name><surname>Peng</surname><given-names>X</given-names></name><name><surname>Lai</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies</article-title>. <source>Lancet Neurol</source>. (<year>2008</year>) <volume>7</volume>:<page-range>1091&#x02013;8</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/s1474-4422(08)70224-2</pub-id>
</mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Peng</surname><given-names>Q</given-names></name><name><surname>Yin</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study</article-title>. <source>Arthritis Res Ther</source>. (<year>2017</year>) <volume>19</volume>:<fpage>259</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s13075-017-1469-8</pub-id>
<pub-id pub-id-type="pmid">29178913</pub-id>
</mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>RA</given-names></name></person-group>. <article-title>Acanthosis nigricans</article-title>. <source>J Am Acad Dermatol</source>. (<year>1994</year>) <volume>31</volume>:<fpage>1</fpage>&#x02013;<lpage>19</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/s0190-9622(94)70128-8</pub-id>
<pub-id pub-id-type="pmid">8021347</pub-id>
</mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>RA</given-names></name></person-group>. <article-title>Sign of leser-tr&#x000e9;lat</article-title>. <source>J Am Acad Dermatol</source>. (<year>1996</year>) <volume>35</volume>:<fpage>88</fpage>&#x02013;<lpage>95</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/s0190-9622(96)90502-2</pub-id>
<pub-id pub-id-type="pmid">8682971</pub-id>
</mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McGavran</surname><given-names>MH</given-names></name><name><surname>Unger</surname><given-names>RH</given-names></name><name><surname>Recant</surname><given-names>L</given-names></name><name><surname>Polk</surname><given-names>HC</given-names></name><name><surname>Kilo</surname><given-names>C</given-names></name><name><surname>Levin</surname><given-names>ME</given-names></name></person-group>. <article-title>A glucagon-secreting alpha-cell carcinoma of the pancreas</article-title>. <source>N Engl J Med</source>. (<year>1966</year>) <volume>274</volume>:<page-range>1408&#x02013;13</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1056/nejm196606232742503</pub-id>
</mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cohen</surname><given-names>PR</given-names></name></person-group>. <article-title>Sweet&#x02019;s syndrome&#x02014;a comprehensive review of an acute febrile neutrophilic dermatosis</article-title>. <source>Orphanet J Rare Dis</source>. (<year>2007</year>) <volume>2</volume>:<elocation-id>34</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/1750-1172-2-34</pub-id>
<pub-id pub-id-type="pmid">17655751</pub-id>
</mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Garc&#x000ed;a-Porr&#x000fa;a</surname><given-names>C</given-names></name><name><surname>Gonz&#x000e1;lez-Gay</surname><given-names>MA</given-names></name></person-group>. <article-title>Cutaneous vasculitis as a paraneoplastic syndrome in adults</article-title>. <source>Arthritis Rheumatol</source>. (<year>1998</year>) <volume>41</volume>:<page-range>1133&#x02013;5</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1002/1529-0131(199806)41:6&#x0003c;1133::aid-art23&#x0003e;3.0.co;2-s</pub-id>
</mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Anderson</surname><given-names>HJ</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>JB</given-names></name></person-group>. <article-title>Paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome: Part I. clinical overview and pathophysiology</article-title>. <source>J Am Acad Dermatol</source>. (<year>2023</year>) <volume>91</volume>:<fpage>1</fpage>&#x02013;<lpage>10</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.jaad.2023.08.020</pub-id>
<pub-id pub-id-type="pmid">37597771</pub-id>
</mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Anderson</surname><given-names>HJ</given-names></name><name><surname>Lee</surname><given-names>JB</given-names></name></person-group>. <article-title>Paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome: Part II. Diagnosis and management</article-title>. <source>J Am Acad Dermatol</source>. (<year>2023</year>) <volume>91</volume>:<fpage>13</fpage>&#x02013;<lpage>22</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.jaad.2023.08.084</pub-id>
<pub-id pub-id-type="pmid">37714216</pub-id>
</mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nadal</surname><given-names>R</given-names></name><name><surname>McMahan</surname><given-names>ZH</given-names></name><name><surname>Antonarakis</surname><given-names>ES</given-names></name></person-group>. <article-title>Paraneoplastic palmar fasciitis and polyarthritis syndrome in a patient with advanced prostate cancer</article-title>. <source>Clin Genitourin Cancer</source>. (<year>2013</year>) <volume>11</volume>:<page-range>e15&#x02013;23</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.clgc.2013.05.008</pub-id>
</mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kassan</surname><given-names>SS</given-names></name><name><surname>Moutsopoulos</surname><given-names>HM</given-names></name></person-group>. <article-title>Clinical manifestations and early diagnosis of Sj&#x000f6;gren syndrome</article-title>. <source>Arch Intern Med</source>. (<year>2004</year>) <volume>164</volume>:<elocation-id>1275</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1001/archinte.164.12.1275</pub-id>
<pub-id pub-id-type="pmid">15226160</pub-id>
</mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Anton</surname><given-names>E</given-names></name></person-group>. <article-title>More on polymyalgia rheumatica (PMR) as a paraneoplastic rheumatic syndrome in the elderly (Bicytopenia and PMR preceding acute myeloid leukemia)</article-title>. <source>J Clin Rheumatol</source>. (<year>2007</year>) <volume>13</volume>:<fpage>114</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1097/01.rhu.0000260650.43402.b6</pub-id>
<pub-id pub-id-type="pmid">17414547</pub-id>
</mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Romanowska-Pr&#x000f3;chnicka</surname><given-names>K</given-names></name><name><surname>Dziewit</surname><given-names>M</given-names></name><name><surname>Lesiak</surname><given-names>A</given-names></name><name><surname>Reich</surname><given-names>A</given-names></name><name><surname>Olesi&#x00144;ska</surname><given-names>M</given-names></name></person-group>. <article-title>Scleroderma and scleroderma-like syndromes</article-title>. <source>Front Immunol</source>. (<year>2024</year>) <volume>15</volume>:<elocation-id>1351675</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fimmu.2024.1351675</pub-id>
<pub-id pub-id-type="pmid">38887288</pub-id>
</mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mart&#x000ed;nez-Lav&#x000ed;n</surname><given-names>M</given-names></name></person-group>. <article-title>Hypertrophic osteoarthropathy</article-title>. <source>Best Pract Res Clin Rheumatol</source>. (<year>2020</year>) <volume>34</volume>:<elocation-id>101507</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.berh.2020.101507</pub-id>
<pub-id pub-id-type="pmid">32291203</pub-id>
</mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Beck</surname><given-names>LH</given-names></name><name><surname>Bonegio</surname><given-names>RG</given-names></name><name><surname>Lambeau</surname><given-names>G</given-names></name><name><surname>Beck</surname><given-names>DM</given-names></name><name><surname>Powell</surname><given-names>DW</given-names></name><name><surname>Cummins</surname><given-names>TD</given-names></name><etal/></person-group>. <article-title>M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy</article-title>. <source>N Engl J Med</source>. (<year>2009</year>) <volume>361</volume>:<fpage>11</fpage>&#x02013;<lpage>21</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1056/nejmoa0810457</pub-id>
<pub-id pub-id-type="pmid">19571279</pub-id>
</mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chong</surname><given-names>WH</given-names></name><name><surname>Molinolo</surname><given-names>AA</given-names></name><name><surname>Chen</surname><given-names>CC</given-names></name><name><surname>Collins</surname><given-names>MT</given-names></name></person-group>. <article-title>Tumor-induced osteomalacia</article-title>. <source>Endocr Relat Cancer</source>. (<year>2011</year>) <volume>18</volume>:<page-range>R53&#x02013;77</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1530/erc-11-0006</pub-id>
</mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Deli&#x000e8;ge</surname><given-names>M</given-names></name><name><surname>Bastens</surname><given-names>B</given-names></name><name><surname>Matus</surname><given-names>G</given-names></name><name><surname>Bl&#x000e9;tard</surname><given-names>N</given-names></name><name><surname>Houbiers</surname><given-names>G</given-names></name><name><surname>Courtois</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Stauffer syndrome: a rare paraneoplastic complication of renal cell carcinoma to be kept in mind</article-title>. <source>Case Rep literature survey Acta Gastroenterol Belg</source>. (<year>2024</year>) <volume>87</volume>:<page-range>40&#x02013;3</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.51821/87.1.11402</pub-id>
</mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Potter</surname><given-names>MJ</given-names></name><name><surname>Adamus</surname><given-names>G</given-names></name><name><surname>Szabo</surname><given-names>SM</given-names></name><name><surname>Lee</surname><given-names>R</given-names></name><name><surname>Mohaseb</surname><given-names>K</given-names></name><name><surname>Behn</surname><given-names>D</given-names></name></person-group>. <article-title>Autoantibodies to transducin in a patient with melanoma-associated retinopathy</article-title>. <source>Am J Ophthalmol</source>. (<year>2002</year>) <volume>134</volume>:<page-range>128&#x02013;30</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/s0002-9394(02)01431-9</pub-id>
</mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Hasman</surname><given-names>RA</given-names></name><name><surname>Barron</surname><given-names>VA</given-names></name><name><surname>Luo</surname><given-names>G</given-names></name><name><surname>Lou</surname><given-names>H</given-names></name></person-group>. <article-title>A nuclear function of HU proteins as neuron-specific alternative RNA processing regulators</article-title>. <source>Mol Biol Cell</source>. (<year>2006</year>) <volume>17</volume>:<page-range>5105&#x02013;14</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1091/mbc.e06-02-0099</pub-id>
</mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lazarova</surname><given-names>DL</given-names></name><name><surname>Spengler</surname><given-names>BA</given-names></name><name><surname>Biedler</surname><given-names>JL</given-names></name><name><surname>Ross</surname><given-names>RA</given-names></name></person-group>. <article-title>HuD, a neuronal-specific RNA-binding protein, is a putative regulator of N-myc pre-mRNA processing/stability in Malignant human neuroblasts</article-title>. <source>Oncogene</source>. (<year>1999</year>) <volume>18</volume>:<page-range>2703&#x02013;10</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/sj.onc.1202621</pub-id>
</mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dalmau</surname><given-names>J</given-names></name><name><surname>Furneaux</surname><given-names>HM</given-names></name><name><surname>Gralla</surname><given-names>RJ</given-names></name><name><surname>Kris</surname><given-names>MG</given-names></name><name><surname>Posner</surname><given-names>JB</given-names></name></person-group>. <article-title>Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer&#x02014;a quantitative western blot analysis</article-title>. <source>Ann Neurol</source>. (<year>1990</year>) <volume>27</volume>:<page-range>544&#x02013;52</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1002/ana.410270515</pub-id>
</mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Verschuuren</surname><given-names>JJ</given-names></name><name><surname>Perquin</surname><given-names>M</given-names></name><name><surname>Velde</surname><given-names>GT</given-names></name><name><surname>De Baets</surname><given-names>M</given-names></name><name><surname>Vriesman</surname><given-names>PVB</given-names></name><name><surname>Twijnstra</surname><given-names>A</given-names></name></person-group>. <article-title>Anti-Hu antibody titre and brain metastases before and after treatment for small cell lung cancer</article-title>. <source>J Neurol Neurosurg Psychiatry</source>. (<year>1999</year>) <volume>67</volume>:<page-range>353&#x02013;7</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1136/jnnp.67.3.353</pub-id>
</mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vigneswara</surname><given-names>V</given-names></name><name><surname>Lowenson</surname><given-names>JD</given-names></name><name><surname>Powell</surname><given-names>CD</given-names></name><name><surname>Thakur</surname><given-names>M</given-names></name><name><surname>Bailey</surname><given-names>K</given-names></name><name><surname>Clarke</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Proteomic identification of novel substrates of a protein isoaspartyl methyltransferase repair enzyme</article-title>. <source>J Biol Chem</source>. (<year>2006</year>) <volume>281</volume>:<page-range>32619&#x02013;29</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1074/jbc.m605421200</pub-id>
</mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shirasawa</surname><given-names>T</given-names></name><name><surname>Endoh</surname><given-names>R</given-names></name><name><surname>Zeng</surname><given-names>Y</given-names></name><name><surname>Sakamoto</surname><given-names>K</given-names></name><name><surname>Mori</surname><given-names>H</given-names></name></person-group>. <article-title>Protein l-isoaspartyl methyltransferase: developmentally regulated gene expression and protein localization in the central nervous system of aged rat</article-title>. <source>Neurosci Lett</source>. (<year>1995</year>) <volume>188</volume>:<fpage>37</fpage>&#x02013;<lpage>40</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/0304-3940(95)11389-e</pub-id>
<pub-id pub-id-type="pmid">7783974</pub-id>
</mixed-citation></ref><ref id="B46"><label>46</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pulido</surname><given-names>MA</given-names></name><name><surname>DerHartunian</surname><given-names>MK</given-names></name><name><surname>Qin</surname><given-names>Z</given-names></name><name><surname>Chung</surname><given-names>EM</given-names></name><name><surname>Kang</surname><given-names>DS</given-names></name><name><surname>Woodham</surname><given-names>AW</given-names></name><etal/></person-group>. <article-title>Isoaspartylation appears to trigger small cell lung cancer-associated autoimmunity against neuronal protein ELAVL4</article-title>. <source>J Neuroimmunol</source>. (<year>2016</year>) <volume>299</volume>:<page-range>70&#x02013;8</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.jneuroim.2016.09.002</pub-id>
</mixed-citation></ref><ref id="B47"><label>47</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mamula</surname><given-names>MJ</given-names></name><name><surname>Gee</surname><given-names>RJ</given-names></name><name><surname>Elliott</surname><given-names>JI</given-names></name><name><surname>Sette</surname><given-names>A</given-names></name><name><surname>Southwood</surname><given-names>S</given-names></name><name><surname>Jones</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Isoaspartyl post-translational modification triggers autoimmune responses to self-proteins</article-title>. <source>J Biol Chem</source>. (<year>1999</year>) <volume>274</volume>:<page-range>22321&#x02013;7</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1074/jbc.274.32.22321</pub-id>
</mixed-citation></ref><ref id="B48"><label>48</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Adamus</surname><given-names>G</given-names></name><name><surname>Bonnah</surname><given-names>R</given-names></name><name><surname>Brown</surname><given-names>L</given-names></name><name><surname>David</surname><given-names>L</given-names></name></person-group>. <article-title>Detection of autoantibodies against heat shock proteins and collapsin response mediator proteins in autoimmune retinopathy</article-title>. <source>BMC Ophthalmol</source>. (<year>2013</year>) <volume>13</volume>:<elocation-id>48</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/1471-2415-13-48</pub-id>
<pub-id pub-id-type="pmid">24066722</pub-id>
</mixed-citation></ref><ref id="B49"><label>49</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Milam</surname><given-names>AH</given-names></name><name><surname>Saari</surname><given-names>JC</given-names></name><name><surname>Jacobson</surname><given-names>SG</given-names></name><name><surname>Lubinski</surname><given-names>WP</given-names></name><name><surname>Feun</surname><given-names>LG</given-names></name><name><surname>Alexander</surname><given-names>KR</given-names></name></person-group>. <article-title>Autoantibodies against retinal bipolar cells in cutaneous melanoma-associated retinopathy</article-title>. <source>Invest Ophthalmol Vis Sci</source>. (<year>1993</year>) <volume>34</volume>:<fpage>91</fpage>&#x02013;<lpage>100</lpage>.<pub-id pub-id-type="pmid">8425845</pub-id>
</mixed-citation></ref><ref id="B50"><label>50</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bazhin</surname><given-names>AV</given-names></name><name><surname>Savchenko</surname><given-names>MS</given-names></name><name><surname>Shifrina</surname><given-names>ON</given-names></name><name><surname>Demoura</surname><given-names>SA</given-names></name><name><surname>Chikina</surname><given-names>SY</given-names></name><name><surname>Jaques</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Recoverin as a paraneoplastic antigen in lung cancer: the occurrence of anti-recoverin autoantibodies in sera and recoverin in tumors</article-title>. <source>Lung Cancer</source>. (<year>2004</year>) <volume>44</volume>:<page-range>193&#x02013;8</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.lungcan.2003.10.006</pub-id>
</mixed-citation></ref><ref id="B51"><label>51</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ohguro</surname><given-names>H</given-names></name><name><surname>Yokoi</surname><given-names>Y</given-names></name><name><surname>Ohguro</surname><given-names>I</given-names></name><name><surname>Mamiya</surname><given-names>K</given-names></name><name><surname>Ishikawa</surname><given-names>F</given-names></name><name><surname>Yamazaki</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Clinical and immunologic aspects of cancer-associated retinopathy</article-title>. <source>Am J Ophthalmol</source>. (<year>2004</year>) <volume>137</volume>:<page-range>1117&#x02013;9</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.ajo.2004.01.010</pub-id>
</mixed-citation></ref><ref id="B52"><label>52</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Goldstein</surname><given-names>SM</given-names></name></person-group>. <article-title>Cancer-associated retinopathy</article-title>. <source>Arch Ophthalmol</source>. (<year>1999</year>) <volume>117</volume>:<elocation-id>1641</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1001/archopht.117.12.1641</pub-id>
<pub-id pub-id-type="pmid">10604671</pub-id>
</mixed-citation></ref><ref id="B53"><label>53</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Catterall</surname><given-names>WA</given-names></name></person-group>. <article-title>Voltage-gated calcium channels</article-title>. <source>Cold Spring Harb Perspect Biol</source>. (<year>2011</year>) <volume>3</volume>:<elocation-id>a003947</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1101/cshperspect.a003947</pub-id>
<pub-id pub-id-type="pmid">21746798</pub-id>
</mixed-citation></ref><ref id="B54"><label>54</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kesner</surname><given-names>VG</given-names></name><name><surname>Oh</surname><given-names>SJ</given-names></name><name><surname>Dimachkie</surname><given-names>MM</given-names></name><name><surname>Barohn</surname><given-names>RJ</given-names></name></person-group>. <article-title>Lambert-Eaton myasthenic syndrome</article-title>. <source>Neurol Clin</source>. (<year>2018</year>) <volume>36</volume>:<page-range>379&#x02013;94</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.ncl.2018.01.008</pub-id>
</mixed-citation></ref><ref id="B55"><label>55</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>O&#x02019;Neill</surname><given-names>JH</given-names></name><name><surname>Murray</surname><given-names>NMF</given-names></name><name><surname>Newsom-Davis</surname><given-names>J</given-names></name></person-group>. <article-title>The Lambert-Eaton myasthenic syndrome</article-title>. <source>Brain</source>. (<year>1988</year>) <volume>111</volume>:<page-range>577&#x02013;96</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1093/brain/111.3.577</pub-id>
</mixed-citation></ref><ref id="B56"><label>56</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lennon</surname><given-names>VA</given-names></name><name><surname>Kryzer</surname><given-names>TJ</given-names></name><name><surname>Griesmann</surname><given-names>GE</given-names></name><name><surname>O&#x02019;Suilleabhain</surname><given-names>PE</given-names></name><name><surname>Windebank</surname><given-names>AJ</given-names></name><name><surname>Woppmann</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes</article-title>. <source>N Engl J Med</source>. (<year>1995</year>) <volume>332</volume>:<page-range>1467&#x02013;75</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1056/nejm199506013322203</pub-id>
</mixed-citation></ref><ref id="B57"><label>57</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Payne</surname><given-names>M</given-names></name><name><surname>Bradbury</surname><given-names>P</given-names></name><name><surname>Lang</surname><given-names>B</given-names></name><name><surname>Vincent</surname><given-names>A</given-names></name><name><surname>Han</surname><given-names>C</given-names></name><name><surname>Newsom-Davis</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Prospective study into the incidence of Lambert Eaton myasthenic syndrome in small cell lung cancer</article-title>. <source>J Thorac Oncol</source>. (<year>2010</year>) <volume>5</volume>:<page-range>34&#x02013;8</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1097/jto.0b013e3181c3f4f1</pub-id>
</mixed-citation></ref><ref id="B58"><label>58</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maddison</surname><given-names>P</given-names></name><name><surname>Lang</surname><given-names>B</given-names></name></person-group>. <article-title>Paraneoplastic neurological autoimmunity and survival in small-cell lung cancer</article-title>. <source>J Neuroimmunol</source>. (<year>2008</year>) <volume>201-202</volume>:<page-range>159&#x02013;62</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.jneuroim.2008.05.024</pub-id>
</mixed-citation></ref><ref id="B59"><label>59</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hansen</surname><given-names>KB</given-names></name><name><surname>Yi</surname><given-names>F</given-names></name><name><surname>Perszyk</surname><given-names>RE</given-names></name><name><surname>Menniti</surname><given-names>FS</given-names></name><name><surname>Traynelis</surname><given-names>SF</given-names></name></person-group>. <article-title>NMDA receptors in the central nervous system</article-title>. <source>Methods Mol Biol</source>. (<year>2017</year>) <volume>1677</volume>:<fpage>1</fpage>&#x02013;<lpage>80</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/978-1-4939-7321-7_1</pub-id>
<pub-id pub-id-type="pmid">28986865</pub-id>
</mixed-citation></ref><ref id="B60"><label>60</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Aci&#x000e9;n</surname><given-names>P</given-names></name><name><surname>Aci&#x000e9;n</surname><given-names>M</given-names></name><name><surname>Ruiz-Maci&#x000e1;</surname><given-names>E</given-names></name><name><surname>Mart&#x000ed;n-Estefan&#x000ed;a</surname><given-names>C</given-names></name></person-group>. <article-title>Ovarian teratoma-associated anti-NMDAR encephalitis: a systematic review of reported cases</article-title>. <source>Orphanet J Rare Dis</source>. (<year>2014</year>) <volume>9</volume>:<elocation-id>157</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s13023-014-0157-x</pub-id>
<pub-id pub-id-type="pmid">25312434</pub-id>
</mixed-citation></ref><ref id="B61"><label>61</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Al-Diwani</surname><given-names>A</given-names></name><name><surname>Theorell</surname><given-names>J</given-names></name><name><surname>Damato</surname><given-names>V</given-names></name><name><surname>Bull</surname><given-names>J</given-names></name><name><surname>McGlashan</surname><given-names>N</given-names></name><name><surname>Green</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Cervical lymph nodes and ovarian teratomas as germinal centres in NMDA receptor-antibody encephalitis</article-title>. <source>Brain</source>. (<year>2022</year>) <volume>145</volume>:<page-range>2742&#x02013;54</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1093/brain/awac088</pub-id>
</mixed-citation></ref><ref id="B62"><label>62</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mangler</surname><given-names>M</given-names></name><name><surname>De Perez</surname><given-names>IT</given-names></name><name><surname>Teegen</surname><given-names>B</given-names></name><name><surname>St&#x000f6;cker</surname><given-names>W</given-names></name><name><surname>Pr&#x000fc;ss</surname><given-names>H</given-names></name><name><surname>Meisel</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Seroprevalence of anti-N-methyl-d-aspartate receptor antibodies in women with ovarian teratoma</article-title>. <source>J Neurol</source>. (<year>2013</year>) <volume>260</volume>:<page-range>2831&#x02013;5</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s00415-013-7074-0</pub-id>
</mixed-citation></ref><ref id="B63"><label>63</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gong</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Shi</surname><given-names>G</given-names></name><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>N</given-names></name><name><surname>Yang</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Absence of NMDA receptor antibodies in patients with ovarian teratoma without encephalitis</article-title>. <source>Neurol Neuroimmunol Neuroinflamm</source>. (<year>2017</year>) <volume>4</volume>:<elocation-id>e340</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1212/nxi.0000000000000344</pub-id>
<pub-id pub-id-type="pmid">28377940</pub-id>
</mixed-citation></ref><ref id="B64"><label>64</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Trillsch</surname><given-names>F</given-names></name><name><surname>Eichhorn</surname><given-names>P</given-names></name><name><surname>Oliveira-Ferrer</surname><given-names>L</given-names></name><name><surname>Kuempfel</surname><given-names>T</given-names></name><name><surname>Burges</surname><given-names>A</given-names></name><name><surname>Mahner</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>No need for NMDA receptor antibody screening in neurologically asymptomatic patients with ovarian teratomas</article-title>. <source>J Neurol</source>. (<year>2017</year>) <volume>265</volume>:<page-range>431&#x02013;2</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s00415-017-8717-3</pub-id>
</mixed-citation></ref><ref id="B65"><label>65</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kotani</surname><given-names>H</given-names></name><name><surname>Matsuda</surname><given-names>KM</given-names></name><name><surname>Yamaguchi</surname><given-names>K</given-names></name><name><surname>Ono</surname><given-names>C</given-names></name><name><surname>Kogo</surname><given-names>E</given-names></name><name><surname>Ogawa</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Diversity and epitope spreading of anti-RNA polymerase III antibodies in systemic sclerosis: a potential biomarker for skin and lung involvement</article-title>. <source>Arthritis Rheumatol</source>. (<year>2024</year>) <volume>77</volume>:<page-range>67&#x02013;79</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1002/art.42975</pub-id>
</mixed-citation></ref><ref id="B66"><label>66</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Joseph</surname><given-names>CG</given-names></name><name><surname>Darrah</surname><given-names>E</given-names></name><name><surname>Shah</surname><given-names>AA</given-names></name><name><surname>Skora</surname><given-names>AD</given-names></name><name><surname>Casciola-Rosen</surname><given-names>LA</given-names></name><name><surname>Wigley</surname><given-names>FM</given-names></name><etal/></person-group>. <article-title>Association of the autoimmune disease scleroderma with an immunologic response to cancer</article-title>. <source>Science</source>. (<year>2013</year>) <volume>343</volume>:<page-range>152&#x02013;7</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1126/science.1246886</pub-id>
</mixed-citation></ref><ref id="B67"><label>67</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Raspotnig</surname><given-names>M</given-names></name><name><surname>Kr&#x000e5;kenes</surname><given-names>T</given-names></name><name><surname>Herdlev&#x000e6;r</surname><given-names>I</given-names></name><name><surname>Haugen</surname><given-names>M</given-names></name><name><surname>Vedeler</surname><given-names>C</given-names></name></person-group>. <article-title>Expression of cerebellar degeneration-related proteins CDR2 and CDR2L in human and rat brain tissue</article-title>. <source>J Neuroimmunol</source>. (<year>2021</year>) <volume>362</volume>:<elocation-id>577766</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.jneuroim.2021.577766</pub-id>
<pub-id pub-id-type="pmid">34823119</pub-id>
</mixed-citation></ref><ref id="B68"><label>68</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Small</surname><given-names>M</given-names></name><name><surname>Treilleux</surname><given-names>I</given-names></name><name><surname>Couillault</surname><given-names>C</given-names></name><name><surname>Pissaloux</surname><given-names>D</given-names></name><name><surname>Picard</surname><given-names>G</given-names></name><name><surname>Paindavoine</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration</article-title>. <source>Acta Neuropathol</source>. (<year>2018</year>) <volume>135</volume>:<page-range>569&#x02013;79</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s00401-017-1802-y</pub-id>
</mixed-citation></ref><ref id="B69"><label>69</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Peter</surname><given-names>E</given-names></name><name><surname>Treilleux</surname><given-names>I</given-names></name><name><surname>Wucher</surname><given-names>V</given-names></name><name><surname>Jougla</surname><given-names>E</given-names></name><name><surname>Vogrig</surname><given-names>A</given-names></name><name><surname>Pissaloux</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Immune and genetic signatures of breast carcinomas triggering Anti-YO-associated paraneoplastic cerebellar degeneration</article-title>. <source>Neurol Neuroimmunol Neuroinflamm</source>. (<year>2022</year>) <volume>9</volume>:<elocation-id>e200015</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1212/nxi.0000000000200015</pub-id>
<pub-id pub-id-type="pmid">35821104</pub-id>
</mixed-citation></ref><ref id="B70"><label>70</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Venuta</surname><given-names>F</given-names></name><name><surname>Rendina</surname><given-names>EA</given-names></name><name><surname>De Giacomo</surname><given-names>T</given-names></name><name><surname>Della Rocca</surname><given-names>G</given-names></name><name><surname>Antonini</surname><given-names>G</given-names></name><name><surname>Ciccone</surname><given-names>AM</given-names></name><etal/></person-group>. <article-title>Thymectomy for myasthenia gravis: a 27-year experience</article-title>. <source>Eur J Cardiothorac Surg</source>. (<year>1999</year>) <volume>15</volume>:<page-range>621&#x02013;5</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/s1010-7940(99)00052-4</pub-id>
</mixed-citation></ref><ref id="B71"><label>71</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Cui</surname><given-names>Y</given-names></name><name><surname>Jia</surname><given-names>R</given-names></name><name><surname>Xue</surname><given-names>L</given-names></name><name><surname>Liang</surname><given-names>H</given-names></name></person-group>. <article-title>Myasthenia gravis in patients with thymoma affects survival rate following extended thymectomy</article-title>. <source>Oncol Lett</source>. (<year>2016</year>) <volume>11</volume>:<page-range>4177&#x02013;82</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3892/ol.2016.4528</pub-id>
</mixed-citation></ref><ref id="B72"><label>72</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhao</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Jing</surname><given-names>M</given-names></name><name><surname>Cai</surname><given-names>W</given-names></name><name><surname>Jin</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>Long-term prognosis in patients with thymoma combined with myasthenia gravis: a propensity score-matching analysis</article-title>. <source>Front Med</source>. (<year>2024</year>) <volume>11</volume>:<elocation-id>1407830</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fmed.2024.1407830</pub-id>
</mixed-citation></ref><ref id="B73"><label>73</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Romi</surname><given-names>F</given-names></name><name><surname>Skeie</surname><given-names>GO</given-names></name><name><surname>Aarli</surname><given-names>JA</given-names></name><name><surname>Gilhus</surname><given-names>NE</given-names></name></person-group>. <article-title>The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies</article-title>. <source>Arch Neurol</source>. (<year>2000</year>) <volume>57</volume>:<elocation-id>1596</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1001/archneur.57.11.1596</pub-id>
<pub-id pub-id-type="pmid">11074791</pub-id>
</mixed-citation></ref><ref id="B74"><label>74</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cetin</surname><given-names>H</given-names></name><name><surname>Beeson</surname><given-names>D</given-names></name><name><surname>Vincent</surname><given-names>A</given-names></name><name><surname>Webster</surname><given-names>R</given-names></name></person-group>. <article-title>The structure, function, and physiology of the fetal and adult acetylcholine receptor in muscle</article-title>. <source>Front Mol Neurosci</source>. (<year>2020</year>) <volume>13</volume>:<elocation-id>581097</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fnmol.2020.581097</pub-id>
<pub-id pub-id-type="pmid">33013323</pub-id>
</mixed-citation></ref><ref id="B75"><label>75</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Radovich</surname><given-names>M</given-names></name><name><surname>Pickering</surname><given-names>CR</given-names></name><name><surname>Felau</surname><given-names>I</given-names></name><name><surname>Ha</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Jo</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>The integrated genomic landscape of thymic epithelial tumors</article-title>. <source>Cancer Cell</source>. (<year>2018</year>) <volume>33</volume>:<fpage>244</fpage>&#x02013;<lpage>258.e10</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.ccell.2018.01.003</pub-id>
<pub-id pub-id-type="pmid">29438696</pub-id>
</mixed-citation></ref><ref id="B76"><label>76</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yasumizu</surname><given-names>Y</given-names></name><name><surname>Ohkura</surname><given-names>N</given-names></name><name><surname>Murata</surname><given-names>H</given-names></name><name><surname>Kinoshita</surname><given-names>M</given-names></name><name><surname>Funaki</surname><given-names>S</given-names></name><name><surname>Nojima</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Myasthenia gravis-specific aberrant neuromuscular gene expression by medullary thymic epithelial cells in thymoma</article-title>. <source>Nat Commun</source>. (<year>2022</year>) <volume>13</volume>:<fpage>5090</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41467-022-31951-8</pub-id>
<pub-id pub-id-type="pmid">36042199</pub-id>
</mixed-citation></ref><ref id="B77"><label>77</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schultz</surname><given-names>A</given-names></name><name><surname>Hoffacker</surname><given-names>V</given-names></name><name><surname>Wilisch</surname><given-names>A</given-names></name><name><surname>Nix</surname><given-names>W</given-names></name><name><surname>Gold</surname><given-names>R</given-names></name><name><surname>Schalke</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Neurofilament is an autoantigenic determinant in myasthenia gravis</article-title>. <source>Ann Neurol</source>. (<year>1999</year>) <volume>46</volume>:<page-range>167&#x02013;75</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1002/1531-8249(199908)46:2&#x0003c;167::aid-ana5&#x0003e;3.0.co;2-7</pub-id>
</mixed-citation></ref><ref id="B78"><label>78</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hektoen</surname><given-names>HH</given-names></name><name><surname>Tsuruda</surname><given-names>KM</given-names></name><name><surname>Fjellbirkeland</surname><given-names>L</given-names></name><name><surname>Nilssen</surname><given-names>Y</given-names></name><name><surname>Brustugun</surname><given-names>OT</given-names></name><name><surname>Andreassen</surname><given-names>BK</given-names></name></person-group>. <article-title>Real-world evidence for pembrolizumab in non-small cell lung cancer: a nationwide cohort study</article-title>. <source>Br J Cancer</source>. (<year>2024</year>) <volume>132</volume>:<page-range>93&#x02013;102</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41416-024-02895-1</pub-id>
</mixed-citation></ref><ref id="B79"><label>79</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kato</surname><given-names>K</given-names></name><name><surname>Cho</surname><given-names>BC</given-names></name><name><surname>Takahashi</surname><given-names>M</given-names></name><name><surname>Okada</surname><given-names>M</given-names></name><name><surname>Lin</surname><given-names>C</given-names></name><name><surname>Chin</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial</article-title>. <source>Lancet Oncol</source>. (<year>2019</year>) <volume>20</volume>:<page-range>1506&#x02013;17</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/s1470-2045(19)30626-6</pub-id>
</mixed-citation></ref><ref id="B80"><label>80</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Janjigian</surname><given-names>YY</given-names></name><name><surname>Shitara</surname><given-names>K</given-names></name><name><surname>Moehler</surname><given-names>M</given-names></name><name><surname>Garrido</surname><given-names>M</given-names></name><name><surname>Salman</surname><given-names>P</given-names></name><name><surname>Shen</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial</article-title>. <source>Lancet</source>. (<year>2021</year>) <volume>398</volume>:<fpage>27</fpage>&#x02013;<lpage>40</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/s0140-6736(21)00797-2</pub-id>
<pub-id pub-id-type="pmid">34102137</pub-id>
</mixed-citation></ref><ref id="B81"><label>81</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>Tang</surname><given-names>H</given-names></name><name><surname>Cui</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>The role of PD-1 signaling in health and immune-related diseases</article-title>. <source>Front Immunol</source>. (<year>2023</year>) <volume>14</volume>:<elocation-id>1163633</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fimmu.2023.1163633</pub-id>
<pub-id pub-id-type="pmid">37261359</pub-id>
</mixed-citation></ref><ref id="B82"><label>82</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Muenst</surname><given-names>S</given-names></name><name><surname>Schaerli</surname><given-names>AR</given-names></name><name><surname>Gao</surname><given-names>F</given-names></name><name><surname>D&#x000e4;ster</surname><given-names>S</given-names></name><name><surname>Trella</surname><given-names>E</given-names></name><name><surname>Droeser</surname><given-names>RA</given-names></name><etal/></person-group>. <article-title>Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer</article-title>. <source>Breast Cancer Res Treat</source>. (<year>2014</year>) <volume>146</volume>:<fpage>15</fpage>&#x02013;<lpage>24</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s10549-014-2988-5</pub-id>
<pub-id pub-id-type="pmid">24842267</pub-id>
</mixed-citation></ref><ref id="B83"><label>83</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vackova</surname><given-names>J</given-names></name><name><surname>Polakova</surname><given-names>I</given-names></name><name><surname>Johari</surname><given-names>SD</given-names></name><name><surname>Smahel</surname><given-names>M</given-names></name></person-group>. <article-title>CD80 expression on tumor cells alters tumor microenvironment and efficacy of cancer immunotherapy by CTLA-4 blockade</article-title>. <source>Cancers</source>. (<year>2021</year>) <volume>13</volume>:<elocation-id>1935</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/cancers13081935</pub-id>
<pub-id pub-id-type="pmid">33923750</pub-id>
</mixed-citation></ref><ref id="B84"><label>84</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Puzanov</surname><given-names>I</given-names></name><name><surname>Diab</surname><given-names>A</given-names></name><name><surname>Abdallah</surname><given-names>K</given-names></name><name><surname>Bingham</surname><given-names>CO</given-names></name><name><surname>Brogdon</surname><given-names>C</given-names></name><name><surname>Dadu</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group</article-title>. <source>J Immunother Cancer</source>. (<year>2017</year>) <volume>5</volume>:<fpage>95</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s40425-017-0300-z</pub-id>
<pub-id pub-id-type="pmid">29162153</pub-id>
</mixed-citation></ref><ref id="B85"><label>85</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brown</surname><given-names>LJ</given-names></name><name><surname>Weppler</surname><given-names>A</given-names></name><name><surname>Bhave</surname><given-names>P</given-names></name><name><surname>Allayous</surname><given-names>C</given-names></name><name><surname>Patrinely</surname><given-names>JR</given-names></name><name><surname>Ott</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders</article-title>. <source>J Immunother Cancer</source>. (<year>2021</year>) <volume>9</volume>:<elocation-id>e002121</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1136/jitc-2020-002121</pub-id>
<pub-id pub-id-type="pmid">33963010</pub-id>
</mixed-citation></ref><ref id="B86"><label>86</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Buckley</surname><given-names>MW</given-names></name><name><surname>Warner</surname><given-names>AB</given-names></name><name><surname>Brahmer</surname><given-names>J</given-names></name><name><surname>Cappelli</surname><given-names>LC</given-names></name><name><surname>Sharfman</surname><given-names>WH</given-names></name><name><surname>Fuchs</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Immune-related encephalitis after immune checkpoint inhibitor therapy</article-title>. <source>Oncologist</source>. (<year>2024</year>) <volume>30</volume>:<page-range>e1&#x02013;9</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1093/oncolo/oyae186</pub-id>
</mixed-citation></ref><ref id="B87"><label>87</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>H&#x000e9;bert</surname><given-names>J</given-names></name><name><surname>Riche</surname><given-names>B</given-names></name><name><surname>Vogrig</surname><given-names>A</given-names></name><name><surname>Mu&#x000f1;iz-Castrillo</surname><given-names>S</given-names></name><name><surname>Joubert</surname><given-names>B</given-names></name><name><surname>Picard</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Epidemiology of paraneoplastic neurologic syndromes and autoimmune encephalitides in France</article-title>. <source>Neurol Neuroimmunol Neuroinflamm</source>. (<year>2020</year>) <volume>7</volume>:<fpage>e883</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1212/nxi.0000000000000883</pub-id>
<pub-id pub-id-type="pmid">32847939</pub-id>
</mixed-citation></ref><ref id="B88"><label>88</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hamada</surname><given-names>N</given-names></name><name><surname>Maeda</surname><given-names>A</given-names></name><name><surname>Takase-Minegishi</surname><given-names>K</given-names></name><name><surname>Kirino</surname><given-names>Y</given-names></name><name><surname>Sugiyama</surname><given-names>Y</given-names></name><name><surname>Namkoong</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Incidence and distinct features of immune checkpoint inhibitor-related myositis from idiopathic inflammatory myositis: a single-center experience with systematic literature review and meta-analysis</article-title>. <source>Front Immunol</source>. (<year>2021</year>) <volume>12</volume>:<elocation-id>803410</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fimmu.2021.803410</pub-id>
<pub-id pub-id-type="pmid">34938300</pub-id>
</mixed-citation></ref><ref id="B89"><label>89</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vinciguerra</surname><given-names>C</given-names></name><name><surname>Bevilacqua</surname><given-names>L</given-names></name><name><surname>Lupica</surname><given-names>A</given-names></name><name><surname>Ginanneschi</surname><given-names>F</given-names></name><name><surname>Piscosquito</surname><given-names>G</given-names></name><name><surname>Rini</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Diagnosis and management of seronegative myasthenia gravis: lights and shadows</article-title>. <source>Brain Sci</source>. (<year>2023</year>) <volume>13</volume>:<elocation-id>1286</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/brainsci13091286</pub-id>
<pub-id pub-id-type="pmid">37759888</pub-id>
</mixed-citation></ref><ref id="B90"><label>90</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Macklin</surname><given-names>M</given-names></name><name><surname>Yadav</surname><given-names>S</given-names></name><name><surname>Jan</surname><given-names>R</given-names></name><name><surname>Reid</surname><given-names>P</given-names></name></person-group>. <article-title>Checkpoint inhibitor-associated scleroderma and scleroderma mimics</article-title>. <source>Pharmaceuticals</source>. (<year>2023</year>) <volume>16</volume>:<elocation-id>259</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/ph16020259</pub-id>
<pub-id pub-id-type="pmid">37259404</pub-id>
</mixed-citation></ref><ref id="B91"><label>91</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jayathilaka</surname><given-names>B</given-names></name><name><surname>Mian</surname><given-names>F</given-names></name><name><surname>Franchini</surname><given-names>F</given-names></name><name><surname>Au-Yeung</surname><given-names>G</given-names></name><name><surname>IJzerman</surname><given-names>M</given-names></name></person-group>. <article-title>Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review</article-title>. <source>Br J Cancer</source>. (<year>2024</year>) <volume>132</volume>:<page-range>51&#x02013;57</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41416-024-02887-1</pub-id>
</mixed-citation></ref><ref id="B92"><label>92</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chennamadhavuni</surname><given-names>A</given-names></name><name><surname>Abushahin</surname><given-names>L</given-names></name><name><surname>Jin</surname><given-names>N</given-names></name><name><surname>Presley</surname><given-names>CJ</given-names></name><name><surname>Manne</surname><given-names>A</given-names></name></person-group>. <article-title>Risk factors and biomarkers for immune-related adverse events: a practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors</article-title>. <source>Front Immunol</source>. (<year>2022</year>) <volume>13</volume>:<elocation-id>779691</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fimmu.2022.779691</pub-id>
<pub-id pub-id-type="pmid">35558065</pub-id>
</mixed-citation></ref><ref id="B93"><label>93</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Daban</surname><given-names>A</given-names></name><name><surname>Gonnin</surname><given-names>C</given-names></name><name><surname>Phan</surname><given-names>L</given-names></name><name><surname>Saldmann</surname><given-names>A</given-names></name><name><surname>Granier</surname><given-names>C</given-names></name><name><surname>Lillo-Lelouet</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)</article-title>. <source>Oncoimmunology</source>. (<year>2023</year>) <volume>12</volume>:<elocation-id>2204754</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1080/2162402x.2023.2204754</pub-id>
<pub-id pub-id-type="pmid">37187974</pub-id>
</mixed-citation></ref><ref id="B94"><label>94</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Borgers</surname><given-names>JSW</given-names></name><name><surname>Van Wesemael</surname><given-names>TJ</given-names></name><name><surname>Gelderman</surname><given-names>KA</given-names></name><name><surname>Rispens</surname><given-names>T</given-names></name><name><surname>Verdegaal</surname><given-names>EME</given-names></name><name><surname>Moes</surname><given-names>DJAR</given-names></name><etal/></person-group>. <article-title>Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanoma</article-title>. <source>J Immunother Cancer</source>. (<year>2024</year>) <volume>12</volume>:<elocation-id>e009215</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1136/jitc-2024-009215</pub-id>
<pub-id pub-id-type="pmid">38945553</pub-id>
</mixed-citation></ref><ref id="B95"><label>95</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Teillaud</surname><given-names>J</given-names></name><name><surname>Houel</surname><given-names>A</given-names></name><name><surname>Panouillot</surname><given-names>M</given-names></name><name><surname>Riffard</surname><given-names>C</given-names></name><name><surname>Dieu-Nosjean</surname><given-names>M</given-names></name></person-group>. <article-title>Tertiary lymphoid structures in anticancer immunity</article-title>. <source>Nat Rev Cancer</source>. (<year>2024</year>) <volume>24</volume>:<page-range>629&#x02013;46</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41568-024-00728-0</pub-id>
</mixed-citation></ref><ref id="B96"><label>96</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xia</surname><given-names>J</given-names></name><name><surname>Xie</surname><given-names>Z</given-names></name><name><surname>Niu</surname><given-names>G</given-names></name><name><surname>Lu</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Xing</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Single-cell landscape and clinical outcomes of infiltrating B cells in colorectal cancer</article-title>. <source>Immunology</source>. (<year>2022</year>) <volume>168</volume>:<page-range>135&#x02013;51</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1111/imm.13568</pub-id>
</mixed-citation></ref><ref id="B97"><label>97</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mazor</surname><given-names>RD</given-names></name><name><surname>Nathan</surname><given-names>N</given-names></name><name><surname>Gilboa</surname><given-names>A</given-names></name><name><surname>Stoler-Barak</surname><given-names>L</given-names></name><name><surname>Moss</surname><given-names>L</given-names></name><name><surname>Solomonov</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Tumor-reactive antibodies evolve from non-binding and autoreactive precursors</article-title>. <source>Cell</source>. (<year>2022</year>) <volume>185</volume>:<fpage>1208</fpage>&#x02013;<lpage>1222.e21</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.cell.2022.02.012</pub-id>
<pub-id pub-id-type="pmid">35305314</pub-id>
</mixed-citation></ref><ref id="B98"><label>98</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kinker</surname><given-names>GS</given-names></name><name><surname>Vitiello</surname><given-names>GAF</given-names></name><name><surname>Diniz</surname><given-names>AB</given-names></name><name><surname>Cabral-Piccin</surname><given-names>MP</given-names></name><name><surname>Pereira</surname><given-names>PHB</given-names></name><name><surname>Carvalho</surname><given-names>MLR</given-names></name><etal/></person-group>. <article-title>Mature tertiary lymphoid structures are key niches of tumour-specific immune responses in pancreatic ductal adenocarcinomas</article-title>. <source>Gut</source>. (<year>2023</year>) <volume>72</volume>:<page-range>1927&#x02013;41</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1136/gutjnl-2022-328697</pub-id>
</mixed-citation></ref><ref id="B99"><label>99</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Germain</surname><given-names>C</given-names></name><name><surname>Gnjatic</surname><given-names>S</given-names></name><name><surname>Tamzalit</surname><given-names>F</given-names></name><name><surname>Knockaert</surname><given-names>S</given-names></name><name><surname>Remark</surname><given-names>R</given-names></name><name><surname>Goc</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer</article-title>. <source>Am J Respir Crit Care Med</source>. (<year>2014</year>) <volume>189</volume>:<page-range>832&#x02013;44</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1164/rccm.201309-1611oc</pub-id>
</mixed-citation></ref><ref id="B100"><label>100</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dieu-Nosjean</surname><given-names>M</given-names></name><name><surname>Antoine</surname><given-names>M</given-names></name><name><surname>Danel</surname><given-names>C</given-names></name><name><surname>Heudes</surname><given-names>D</given-names></name><name><surname>Wislez</surname><given-names>M</given-names></name><name><surname>Poulot</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures</article-title>. <source>J Clin Oncol</source>. (<year>2008</year>) <volume>26</volume>:<page-range>4410&#x02013;7</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1200/jco.2007.15.0284</pub-id>
</mixed-citation></ref><ref id="B101"><label>101</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Peperzak</surname><given-names>V</given-names></name><name><surname>Veraar</surname><given-names>EAM</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>B&#x00105;ba&#x00142;a</surname><given-names>N</given-names></name><name><surname>Thiadens</surname><given-names>K</given-names></name><name><surname>Brugmans</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>CD8+ T cells produce the chemokine CXCL10 in response to CD27/CD70 costimulation to promote generation of the CD8+ effector T cell pool</article-title>. <source>J Immunol</source>. (<year>2013</year>) <volume>191</volume>:<page-range>3025&#x02013;36</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.4049/jimmunol.1202222</pub-id>
</mixed-citation></ref></ref-list></back></article>